Health Condition 1: K758- Other specified inflammatory liverdiseases
Conditions
Interventions
Intervention1: SAROGLITAZAR: Dose- 4mg
Frequency- once daily
Route of administration- oral
Duration - 6 months
Patients with and without diabetes will be receiving saroglitazar. Effect of drug throug
Sponsors
Arsh gupta
Eligibility
Inclusion criteria
Inclusion criteria: Presence of fatty liver on ultrasound Patients with Type2DM Patients without diabetes
Exclusion criteria
Exclusion criteria: presence of chronic hepatitis B or C infection (positive Hbs Ag or anti HCV Ab) , significant alcohol intake ( >20 gm/ day for males and >10 gm/day for females). Cases with a history of intake of hepatotoxic drugs, drugs leading to hepatic fibrosis or drugs supposed to decrease hepatic fibrosis ( obeticholic acid, vitamin E , pioglitazone, UDCA, omega fatty acid ) , documented cases of autoimmune hepatitis, hepatic storage disorders such as hemochromatosis and Wilson’s disease will be excluded. Patients having others co-morbidities like hypothyroidism, ischemic heart disease or chronic kidney disease will not be included. Pregnant patient will not be included.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Liver Stiffness measurement score by FibroscanTimepoint: once before initition of drug and once after completion of 6 months course of drug | — |
Secondary
| Measure | Time frame |
|---|---|
| SGOT SGPT TPC APRI FIB 4 NAFLD FIBROSIS SCORETimepoint: 6 MONTHS | — |
Countries
India
Contacts
Public ContactDr ARSH GUPTA
IMS and SUM hospital
Outcome results
None listed